Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen and Agilent Technologies have jointly announced a confidential settlement of multiple patent litigations pending between the two companies.
Subscribe to our email newsletter
Under the terms of the agreement, Agilent will make an undisclosed settlement payment to Invitrogen. In addition, Agilent will discontinue sales of its RNase H minus RT products and Invitrogen will obtain a license from Agilent and pay an undisclosed royalty to sell its DNA polymerase blend products. All litigation will be dismissed.
The settlement resolves three patent infringement lawsuits between Invitrogen and Stratagene. Agilent acquired Stratagene in 2007.